يعرض 1 - 10 نتائج من 10 نتيجة بحث عن '"Espiramicina"', وقت الاستعلام: 1.03s تنقيح النتائج
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
    مورد إلكتروني

    عناروين إضافية: Efecto del tratamiento prenatal con espiramicina en la frecuencia de retinocoroiditis por toxoplasmosis congénita en una cohorte colombiana

    المصدر: Biomedica; Vol. 37 No. Sup.1 (2017): Suplemento 1, Alteraciones del sistema nervioso; 86-91; Biomédica; Vol. 37 Núm. Sup.1 (2017): Suplemento 1, Alteraciones del sistema nervioso; 86-91; 2590-7379; 0120-4157

    URL: https://revistabiomedica.org/index.php/biomedica/article/view/2818
    https://revistabiomedica.org/index.php/biomedica/article/view/2818/3453
    https://revistabiomedica.org/index.php/biomedica/article/view/2818/3550
    https://revistabiomedica.org/index.php/biomedica/article/view/2818/3453
    https://revistabiomedica.org/index.php/biomedica/article/view/2818/3550
    *ref*/Baquero-Artigao F, del Castillo-Martín F, Fuentes-Corripio I, Goncé-MellgrenA, Fortuny-Guasch C, de la Calle Fernández-Miranda M, et al. The Spanish Society of Pediatric Infectious Diseases Guidelines for the diagnosis and treatment of congenital toxoplasmosis. An Pediatr (Barc). 2013;79:116.e1-116.e16. http://dx.doi.org/10.1016/j.anpedi.2012.12.001
    *ref*/De la Torre A, González G, Díaz-Ramírez J, Gómez-Marín JE. Screening by ophthalmoscopy for Toxoplasma retinochoroiditis in Colombia. Am J Ophthalmol. 2007;143:354-6. http://dx.doi.org/10.1016/j.ajo.2006.09.048
    *ref*/Arévalo JF, Belfort R Jr, Muccioli C, Espinoza JV. Ocular toxoplasmosis in the developing world. Int Ophthalmol Clin. 2010;50:57-69. http://dx.doi.org/10.1097/IIO.0b013e3181d26bf4
    *ref*/Hernández DL, Donado JH, De La Cruz C, Montoya JC. Antibióticos sistémicos para retinocoroiditis por toxoplasmosis. Revisión sistemática de la literatura. Medicina UPB. 2012;31:170-80.
    *ref*/Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47:554-66. http://dx.doi.org/10.1086/590149
    *ref*/Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013;112:1099-101. http://dx.doi.org/10.1016/B978-0-444-52910-7.00028-3
    *ref*/Gómez-Marín JE. Evaluación del tratamiento de la toxoplasmosis gestacional en una cohorte colombiana. Infectio.2005;9:16-23.
    *ref*/Avelino MM, Amaral WN, Rodrigues IM, Rassi AR, Gomes MB, Costa TL, et al. Congenital toxoplasmosis and prenatal care state programs. BMC Infect Dis. 2014;18:14-33. http://dx.doi.org/10.1186/1471-2334-14-33
    *ref*/Wallon M, Garweg JG, Abrahamowicz M, Cornu C, Vinault S, Quantin C, et al. Ophthalmic outcomes of congenital toxoplasmosis followed until adolescence. Pediatrics. 2014;133:e601-8. http://dx.doi.org/10.1542/peds.2013-2153
    *ref*/Faucher B, García-Meric P, Franck J, Minodier P, Francois P, Gonnet S, et al. Long-term ocular outcome in congenital toxoplasmosis: A prospective cohort of treated children. J Infect. 2012;64:104-9. http://dx.doi.org/10.1016/j.jinf.2011.10.008
    *ref*/Kijlstra A, Petersen E. Epidemiology, pathophysiology, and the future of ocular toxoplasmosis. Ocul Immunol Inflamm. 2014;22:138-47. http://dx.doi.org/10.3109/09273948.2013.823214
    *ref*/Petersen E, Kijlstra A, Stanford M. Epidemiology of ocular toxoplasmosis. Ocul Immunol Inflamm. 2012;20:68-75. http://dx.doi.org/10.3109/09273948.2012.661115
    *ref*/Holland GN. Ocular toxoplasmosis: A global reassessment. Part I: Epidemiology and course of disease. Am J phthalmol.2003;136:973-88. http://dx.doi.org/10.1016/j.ajo.2003.09.040
    *ref*/Silveira C, Belfort RJ, Burnier MJ, Nussenblatt R. Acquired toxoplasmic infection as the cause of toxoplasmic retinochoroiditis in families. Am J Ophthalmol 1988;106:362-4.
    *ref*/Gómez-Marín JE, De la Torre A, Ángel-Muller E, Rubio J, Arenas J, Osorio E, et al. First Colombian multicentric newborn screening for congenital toxoplasmosis. PLoS Negl Trop Dis. 2011;5:e1195. http://dx.doi.org/10.1371/journal.pntd.0001195
    *ref*/Rosso F, Les JT, Agudelo A, Villalobos C, Chaves JA, Tunubala GA, et al. Prevalence of infection with Toxoplasma gondii among pregnant women in Cali, Colombia, South America. Am J Trop Med Hyg. 2008;78:504-8.
    *ref*/Gómez-Marín JE, González MM, Montoya MT, Giraldo A, Castaño JC. A newborn screening programme for congenital toxoplasmosis in the setting of a country with less income. Arch Dis Child. 2007;92:88. http://dx.doi.org/10.1136/adc.2006.106922
    *ref*/Díaz A, Aristizábal BH. Métodos tradicionales y moleculares en el diagnóstico de la toxoplasmosis y su aplicación en el contexto clínico. Medicina UPB. 2013;32:54-67.
    *ref*/Gilbert R, Dezateux C. Newborn screening for congenital toxoplasmosis: Feasible, but benefits are not established. Arch Dis Child. 2006;91:629-31. http://dx.doi.org/10.1136/adc.2006.094870
    *ref*/Rodrigues IM, Costa TL, Avelar JB, Amaral WN, Castro AM, Avelino MM. Assessment of laboratory methods used in the diagnosis of congenital toxoplasmosis after maternal treatment with spiramycin in pregnancy. BMC Infect Dis. 2014;14:349. http://dx.doi.org/10.1186/1471-2334-14-349.
    *ref*/Paquet C, Yudin MH. Toxoplasmosis in pregnancy: Prevention, screening, and treatment. J Obstet Gynaecol Can. 2013;35:78-81. http://dx.doi.org/10.1016/S1701-2163(15)31053-7
    *ref*/Mandelbrot L. Prevention of mother-to-child transmission of toxoplasmosis: Perspectives. Gynecol Obstet Fertil. 2012;40:591-8. http://dx.doi.org/10.1016/j.gyobfe.2012.07.033
    *ref*/Serranti D, Buonsenso D, Valentini P. Congenital toxoplasmosis treatment. Eur Rev Med Pharmacol Sci. 2011;15:193-8.
    *ref*/Gómez-Marín JE, De laTorre A. Positive benefit of postnatal treatment in congenital toxoplasmosis. Arch Dis Child. 2007;92:88-9.
    *ref*/Cortina-Borja M, Tan HK, Wallon M, Paul M, Prusa A, Buffolano W, et al. Prenatal treatment for serious neurological sequelae of congenital toxoplasmosis: An observational prospective cohort study. PLoS Med. 2010;7. http://dx.doi.org/10.1371/journal.pmed.1000351
    *ref*/Valentini P, Annunziata ML, Angelone DF, Masini L, De Santis M, Testa A, et al. Role of spiramycin/cotrimoxazole association in the mother-to-child transmission of toxoplasmosis infection in pregnancy. Eur J Clin Microbiol Infect Dis. 2009;28:297-300. http://dx.doi.org/10.1007/s10096-008-0612-5
    *ref*/Cortés JA, Gómez JE, Silva PI, Arévalo L, Arévalo I, Álvarez MI, et al. Guía de atención integral para la prevención, detección temprana y tratamiento de las complicaciones del embarazo, parto y puerperio: sección toxoplasmosis en el embarazo. Infectio. 2012;16:230-46.
    *ref*/Gómez JE, Ruiz B, Silva P, Beltrán S, Cortés J, Montoya J, et al. Guía de práctica clínica para toxoplasmosis durante el embarazo y toxoplasmosis congénita en Colombia. Infectio. 2007;11:129-41.
    *ref*/SYROCOT (Systematic Review on Congenital Toxoplasmosis) study group, Thiébaut R, Leproust S, Chêne G, Gilbert R. Effectiveness of prenatal treatment for congenital toxoplasmosis: A meta-analysis of individual patients’ data. Lancet. 2007;369:115-22. http://dx.doi.org/10.1016/S0140-6736(07)60072-5

  8. 8
    مورد إلكتروني

    المصدر: Revista de la Facultad de Medicina Veterinaria y de Zootecnia; Vol. 44 Núm. 1 (1996); 3-6; Revista de la Facultad de Medicina Veterinaria y de Zootecnia; Vol. 44 No. 1 (1996); 3-6; Revista de la Facultad de Medicina Veterinaria y de Zootecnia; v. 44 n. 1 (1996); 3-6; 2357-3813; 0120-2952

    URL: https://revistas.unal.edu.co/index.php/remevez/article/view/94471/78797
    https://revistas.unal.edu.co/index.php/remevez/article/view/94471/78797
    *ref*/COTRINO, B. V. Mastitis bovina: pautas para prevenir y controlar la mastitis a nivel de finca. Revista ANALAC. Bogotá. 57:33-80. Abril, 1985. CRIST, L. W.; HARMON, J. R. Controlling mastitis. The problem, its impact and future perspectives. In: biotechnology in the food industry. Alletech Technical Publication. Kentucky. pp. 266, 270, 273. 1981. HEWITT, W. 1977. Microbiological assay.Academic Press Inc. London. pp. 19, 57, 183. OLIVER, S. P. AND SMITH, K.L. Importance of the dry period in the control of intramamary infections by environmental pathogens. In: 26th Annual Meeting. National Mastitis Council. Orlando 1987. pp 81-92. RODRIGUEZ, G. La mastitis bovina y el potencial para su control en la Sabana de Bogotá Informe técnico No. 2. Proyecto Colombo Alemán ICA-GTZ. 1988. pp. 22, 71. SANDERS, P. Pharmacoquinetics of spiramycin after ntravenous, intramuscular and subcutaneous administraron lactacting cows. Journal Vet. Pharmacol. Therapy. 15: 13-61. 1992. SOBACK S, ZIV G. and WINKLER M. Sistemic dry cow therapy, a preliminary report. J. Dairy Sci. 73(3): 661. 1990. ZIV, G. Profil pharmacocinetiqe de la spiramycine chez les brevis et le vaches laitieres. Can. Med. Vet. 43: 371-390. 1974. ZIV, G. Drug selection and use in mastitis. Systemic versus local therapy. JAVMA. 176: 1109-1117. May 1980.

  9. 9
    مورد إلكتروني

    المصدر: Revista de la Facultad de Medicina Veterinaria y de Zootecnia; Vol. 44 Núm. 1 (1996); 3-6; Revista de la Facultad de Medicina Veterinaria y de Zootecnia; Vol. 44 No. 1 (1996); 3-6; Revista de la Facultad de Medicina Veterinaria y de Zootecnia; v. 44 n. 1 (1996); 3-6; 2357-3813; 0120-2952

    URL: https://revistas.unal.edu.co/index.php/remevez/article/view/94471/78797
    https://revistas.unal.edu.co/index.php/remevez/article/view/94471/78797
    *ref*/COTRINO, B. V. Mastitis bovina: pautas para prevenir y controlar la mastitis a nivel de finca. Revista ANALAC. Bogotá. 57:33-80. Abril, 1985. CRIST, L. W.; HARMON, J. R. Controlling mastitis. The problem, its impact and future perspectives. In: biotechnology in the food industry. Alletech Technical Publication. Kentucky. pp. 266, 270, 273. 1981. HEWITT, W. 1977. Microbiological assay.Academic Press Inc. London. pp. 19, 57, 183. OLIVER, S. P. AND SMITH, K.L. Importance of the dry period in the control of intramamary infections by environmental pathogens. In: 26th Annual Meeting. National Mastitis Council. Orlando 1987. pp 81-92. RODRIGUEZ, G. La mastitis bovina y el potencial para su control en la Sabana de Bogotá Informe técnico No. 2. Proyecto Colombo Alemán ICA-GTZ. 1988. pp. 22, 71. SANDERS, P. Pharmacoquinetics of spiramycin after ntravenous, intramuscular and subcutaneous administraron lactacting cows. Journal Vet. Pharmacol. Therapy. 15: 13-61. 1992. SOBACK S, ZIV G. and WINKLER M. Sistemic dry cow therapy, a preliminary report. J. Dairy Sci. 73(3): 661. 1990. ZIV, G. Profil pharmacocinetiqe de la spiramycine chez les brevis et le vaches laitieres. Can. Med. Vet. 43: 371-390. 1974. ZIV, G. Drug selection and use in mastitis. Systemic versus local therapy. JAVMA. 176: 1109-1117. May 1980.

  10. 10
    دورية أكاديمية

    عنوان ترانسليتريتد: Guía de la Sociedad Española de Infectología Pediátrica para el diagnóstico y tratamiento de la toxoplasmosis congénita.

    المؤلفون: Baquero-Artigao F; Coordinadores del documento, Unidad de Enfermedades Infecciosas, Hospital Infantil La Paz, Madrid, Spain. fbaquero@terra.es, del Castillo Martín F, Fuentes Corripio I, Goncé Mellgren A, Fortuny Guasch C, de la Calle Fernández-Miranda M, González-Tomé MI, Couceiro Gianzo JA, Neth O, Ramos Amador JT

    المصدر: Anales de pediatria (Barcelona, Spain : 2003) [An Pediatr (Barc)] 2013 Aug; Vol. 79 (2), pp. 116.e1-116.e16. Date of Electronic Publication: 2013 Jan 23.

    نوع المنشور: English Abstract; Journal Article; Practice Guideline

    بيانات الدورية: Publisher: Elsevier España Country of Publication: Spain NLM ID: 101162596 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1695-9531 (Electronic) Linking ISSN: 16954033 NLM ISO Abbreviation: An Pediatr (Barc) Subsets: MEDLINE